Startups
2023
D-SIGHT SLGame-changing treatments for retinal neurodegenerative diseases
First-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.
First-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.
Address
Carrer de la Vall d'Hebron, 08035 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
D-Sight is founded and lead by world leaders in diabetic retinopathy, diabetes and other neurodegenerative diseases linked to the retina.
Value proposition
Efficacy: IN THE PREVENTION AND TREATMENT OF EARLY STAGES OF DIABETIC RETINOPATHY, WITH NO ASSOCIATED SIDE-EFFECTS.
Administration: OUR SOLUTION IS NON-INVASIVE AND SELF-ADMINISTRABLE.
Strong IP strategy: OUR PATENT FAMILY IS PRESENT IN 22 COUNTRIES WORLDWIDE.
Cost-effective: OUR TREATMENT IS CHEAPER THAN OTHER AVAILABLE THERAPIES, REPRESENTING A COST-SAVING SOLUTION FOR NATIONAL HEALTHCARE SYSTEMS IN THE WORLD.
Value proposition
Efficacy: IN THE PREVENTION AND TREATMENT OF EARLY STAGES OF DIABETIC RETINOPATHY, WITH NO ASSOCIATED SIDE-EFFECTS.
Administration: OUR SOLUTION IS NON-INVASIVE AND SELF-ADMINISTRABLE.
Strong IP strategy: OUR PATENT FAMILY IS PRESENT IN 22 COUNTRIES WORLDWIDE.
Cost-effective: OUR TREATMENT IS CHEAPER THAN OTHER AVAILABLE THERAPIES, REPRESENTING A COST-SAVING SOLUTION FOR NATIONAL HEALTHCARE SYSTEMS IN THE WORLD.
Product description
Improving the quality of life of diabetic patients
We have developed a first-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.
D-Sight addresses a wide-spread unmet medical need with a cost-effective, non-invasive and safe treatment, which also prevents side-effects and limitations associated to current standard-of-care therapies.
Solution
D-Sight has developed a new innovative therapeutic approach for the prevention and treatment of early stages of diabetic retinopathy based on the topical ocular administration of DPP-IV inhibitors.
Our solution prevents neurodegeneration and the early microvascular alterations linked to these early stages of the disease.
We have developed a first-in-class solution for the prevention and treatment of early stages of diabetic retinopathy.
D-Sight addresses a wide-spread unmet medical need with a cost-effective, non-invasive and safe treatment, which also prevents side-effects and limitations associated to current standard-of-care therapies.
Solution
D-Sight has developed a new innovative therapeutic approach for the prevention and treatment of early stages of diabetic retinopathy based on the topical ocular administration of DPP-IV inhibitors.
Our solution prevents neurodegeneration and the early microvascular alterations linked to these early stages of the disease.